This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for PepsiCo, QUALCOMM & HSBC
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), QUALCOMM Incorporated (QCOM) and HSBC Holdings plc (HSBC).
Illumina Q2 Preview: 8th Consecutive EPS Beat in Store?
by Derek Lewis
Just in its latest quarter, ILMN registered a solid 23% bottom-line beat.
Celularity, Inc. (CELU) Q2 Earnings Beat Estimates
by Zacks Equity Research
Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 32.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Most-Watched Stock Illumina, Inc. (ILMN) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Illumina (ILMN). This makes it worthwhile to examine what the stock has in store.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $215.61, moving -0.49% from the previous trading session.
Top Stock Picks for Week of August 1, 2022
by Panel Of Zacks Experts
A Medical Stock with a Solid Earnings Outlook and a Retailer with a Compelling Growth Story.
A Nonfarm Jobs Update: Global Week Ahead
by John Blank
Stock traders must factor in macro cooling across a full range of economies.This implies U.S. post-COVID job adds slow down.
Illumina and Best Buy have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Illumina and Best Buy are part of Zacks Bull and Bear of the Day article.
Bull of the Day: Illumina (ILMN)
by Kevin Cook
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
Illumina (ILMN) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $199.29 in the latest trading session, marking a -0.11% move from the prior day.
BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BIIB vs. ILMN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina
by Zacks Equity Research
Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina have been included in this Analyst Blog.
Top Analyst Reports for Johnson & Johnson, Cigna, & Vertex
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis
by Zacks Equity Research
Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.
Illumina (ILMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $193.93, moving +0.2% from the previous trading session.
Do Options Traders Know Something About Illumina (ILMN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina's (ILMN) GRAIL to Assess Galleri Test With New Deal
by Zacks Equity Research
Illumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.
Here's Why Investors Should Retain Illumina (ILMN) Stock Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.
Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI
by Zacks Equity Research
Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.
Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger
by Zacks Equity Research
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.
Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up
by Zacks Equity Research
Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.
Illumina (ILMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 22.99% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
QGEN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. ILMN: Which Stock Is the Better Value Option?